Antifungal agents: mechanisms of action

Scherer, 2002, Gene discovery and comparative genomics: progress and prospects, 259

Denning, 2002, Sequencing the Aspergillus fumigatus genome, Lancet Infect. Dis., 2, 251, 10.1016/S1473-3099(02)00243-8

Schein, 2002, Physical maps for genome analysis of serotype A and D strains of the fungal pathogen Cryptococcus neoformans, Genome Res., 12, 1445, 10.1101/gr.81002

Goffeau, 1997, The yeast genome directory, Nature, 387, 5, 10.1038/387s005

De Backer, 2002, Functional genomics approaches for the identification and validation of antifungal drug targets, Am. J. Pharmacogenomics, 2, 113, 10.2165/00129785-200202020-00004

Horrobin, 2001, Realism in drug discovery – could Cassandra be right?, Nat. Biotechnol., 19, 1099, 10.1038/nbt1201-1099

Odds, 2001, Sordarin antifungal agents, Expert Opin. Ther. Pat., 11, 283, 10.1517/13543776.11.2.283

Edmond, 1999, Nosocomial bloodstream infections in United States hospitals: a three-year analysis, Clin. Infect. Dis., 29, 239, 10.1086/520192

Trick, 2002, Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999, Clin. Infect. Dis., 35, 627, 10.1086/342300

Yamazaki, 1999, Epidemiology of visceral mycoses: analysis of data in Annual of the Pathological Autopsy Cases in Japan, J. Clin. Microbiol., 37, 1732, 10.1128/JCM.37.6.1732-1738.1999

Develoux, 2001, Griseofulvin, Ann. Dermatol. Veneréol., 128, 1317

Woyke, 2002, Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans, Antimicrob. Agents Chemother., 46, 3802, 10.1128/AAC.46.12.3802-3808.2002

Pfaller, 2002, In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using national committee for clinical laboratory standards susceptibility testing methods, Antimicrob. Agents Chemother., 46, 3518, 10.1128/AAC.46.11.3518-3521.2002

Brajtburg, 1974, The molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal oils, Antimicrob. Agents Chemother., 5, 377, 10.1128/AAC.5.4.377

Dupont, 2002, Overview of the lipid formulations of amphotericin B, J. Antimicrob. Chemother., 49, 31, 10.1093/jac/49.suppl_1.31

Zarif, 2000, Cochleates: new lipid-based drug delivery system, J. Liposome Res., 10, 523, 10.3109/08982100009031116

Falk, 1999, A novel injectable water-soluble amphotericin B-arabinogalactan conjugate, Antimicrob. Agents Chemother., 43, 1975, 10.1128/AAC.43.8.1975

Anonymous (2001) Liposomal nystatin – Nyotran® – Antifungal. Drugs Future 26, 810.

Vanden Bossche, 1995, P450 inhibitors of use in medical treatment: focus on mechanisms of action, Pharmacol. Ther., 67, 79, 10.1016/0163-7258(95)00011-5

Kelly, 1997, Characterization of Saccharomyces cerevisiae cyp61, sterol Δ22-desaturase, and inhibition by azole antifungal agents, J. Biol. Chem., 272, 9986, 10.1074/jbc.272.15.9986

Marichal, 1985, The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger, Sabouraudia, 22, 13, 10.1080/00362178585380041

Podust, 2001, Crystal structure of cytochrome P450 14 alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors, Proc. Natl. Acad. Sci. U. S. A., 98, 3068, 10.1073/pnas.061562898

Podust, 2001, Substrate recognition sites in 14α-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51, J. Inorg. Biochem., 87, 227, 10.1016/S0162-0134(01)00388-9

Sanglard, 2002, Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences, Lancet Infect. Dis., 2, 73, 10.1016/S1473-3099(02)00181-0

Espinel-Ingroff, 2001, In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature, Mycopathologia, 150, 101, 10.1023/A:1010954803886

Ghannoum, 2002, Voriconazole – better chances for patients with invasive mycoses, Eur. J. Med. Res., 7, 242

Gonzalez, 2001, In vitro and in vivo activities of posaconazole against Coccidioides immitis, Antimicrob. Agents Chemother., 46, 1352, 10.1128/AAC.46.5.1352-1356.2002

Vanden Bossche, 2002, Echinocandins – an update, Expert Opin. Ther. Pat., 12, 151, 10.1517/13543776.12.2.151

Douglas, 2001, Fungal β(1,3)-D-glucan synthesis, Med. Mycol., 39, 55, 10.1080/mmy.39.1.55.66

Letscher-Bru, 2003, Caspofungin: the first representative of a new antifungal class, J. Antimicrob. Chemother., 51, 513, 10.1093/jac/dkg117

Dominguez, 1998, Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans, Antimicrob. Agents Chemother., 42, 2279, 10.1128/AAC.42.9.2279